Chemotherapy in metastatic retinoblastoma.
Eleven children with metastatic retinoblastoma diagnosed during the period 1970-1984 were treated with chemotherapy. Short-term complete responses were observed in three children treated with a four-drug combination which included cisplatinum, and in one child treated with vincristine and cyclophosphamide. The median duration of survival of the 11 children receiving chemotherapy was nine months, whilst the median survival of 13 children with metastatic retinoblastoma who were not given chemotherapy was only 2.3 months (p = 0.06). This suggests that retinoblastoma is a chemosensitive tumour and therefore adjuvant chemotherapy may have a role in children with retinoblastoma who at diagnosis are thought to be at high risk of developing metastatic disease.
D000677:Amsacrine / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D005134:Eye Neoplasms / Q000188:drug therapy*; D006801:Humans; D012175:Retinoblastoma / Q000188:drug therapy / Q000556:secondary*; D013713:Teniposide / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D000677:Amsacrine; D014750:Vincristine; D003520:Cyclophosphamide; D013713:Teniposide; D002945:Cisplatin